

FOR IMMEDIATE RELEASE

ASCPT Names New Board Member

Alexandria, Va. (January 23, 2019) — The American Society for Clinical Pharmacology and Therapeutics (ASCPT) Board of Directors welcomes its newest member, Tamorah Lewis, MD, PhD. Dr. Lewis will join the ASCPT board as an at-large director in March 2019.

Dr. Lewis is a neonatologist at Children's Mercy Hospital, MO, and an assistant professor of pediatrics at the University of Missouri–Kansas City School of Medicine.

Dr. Lewis earned her doctoral degree from Johns Hopkins School of Medicine in 2007. In 2014, she received the esteemed Food and Drug Administration (FDA) ORISE Fellowship while working toward her PhD in clinical investigation at Hopkins' Bloomberg School of Public Health. She completed postdoctoral training in pediatrics, neonatology, and clinical pharmacology at Hopkins.



Dr. Tamorah Lewis

An expert on drug exposure, safety, and toxicity in newborns, Dr. Lewis leads multiple National Institutes of Health–funded studies on neonatal and perinatal pharmacology. She is an American Academy of Pediatrics (AAP) representative for the Centers for Disease Control and Prevention's Plague Clinical Guidelines Development Project and a member of the AAP Section on Clinical Pharmacology and Therapeutics Executive Committee. Dr. Lewis is also a consultant and special government employee for the FDA Pediatric Advisory Committee, and she participates on several committees for Children's Mercy Hospital. From 2017 to 2018, she served on ASCPT's Scientific Program Committee.

Dr. Lewis is a review editor for *Obstetric and Pediatric Pharmacology* and a reviewer for the *Journal of Clinical Pharmacology*, *Frontiers in Pharmacology*, and the *British Journal of Clinical Pharmacology*. She has presented lectures on pediatric therapeutics at numerous national and international meetings.

About ASCPT

ASCPT is the leading forum for the discussion, development, and integration of clinical pharmacology, translational medicine, and therapeutics. A pillar of the scientific community for more than 100 years, ASCPT is committed to advancing the study and practice of translational medicine.

Contact:

Sharon Swan, FASAE, CAE
CEO, ASCPT
703-836-6981, Ext. 100
Sharon@ascpt.org